GlaxoSmithKline has decided to discontinue supply of its ‘Infanrix IPV’ vaccine, which protects against diphtheria, tetanus, pertussis, and polio in children, in South Korea.

Infanrix IPV and Sanofi Pasteur's ‘Tetraxim’ are the only DTaP-IPV vaccines used in the National Immunization Program (NIP), raising concerns about the shortage of vaccines and the shortage of vaccinations that will follow.

GSK reported to the MFDS that it will discontinue the supply of Infanrix IPV Prefilled Syringe as of July 1.

The reason for the suspension is low domestic demand. The company said, "It is difficult to import additional supply, and it will not be possible for the company to part